A recent study from the Perelman School of Medicine at the University of Pennsylvania reveals that introducing anti-obesity medication just one month after the initiation of behavioral therapy can significantly enhance weight loss results, particularly for patients who experience minimal success with lifestyle changes alone. Published in Nature Medicine, the research challenges current guidelines that suggest waiting up to six months before considering medications.
Obesity, which affects over 40% of American adults, is a key factor in the development of heart disease, stroke, type 2 diabetes, and certain cancers. While both behavioral therapy (lifestyle interventions) and anti-obesity drugs have been shown to aid weight loss, their effectiveness varies from person to person. This new study fills an important gap by showing that combining different treatment modalities can significantly boost success for those who struggle with a single approach.
Traditionally, obesity management guidelines advocate for a minimum of six months of behavioral therapy, which includes calorie reduction, physical activity, and behavior modification techniques. These interventions are designed to help individuals establish long-term, sustainable weight loss habits through personalized counseling and goal-setting. However, research indicates that up to 50% of patients fail to lose at least 5% of their body weight with these methods alone.
Dr. Jena Shaw Tronieri, a Senior Research Investigator at the Center for Weight and Eating Disorders, emphasized the limited understanding of how to support patients who do not see results from behavioral interventions. “Some experts have suggested adding an anti-obesity medication for those who struggle, but until now, no studies have explored whether this approach actually improves weight loss,” she said.
Accelerating Weight Loss through Early Intervention
The study focused on patients who showed less than a 2% reduction in body weight after one month of weekly behavioral therapy sessions. These individuals were categorized as “early non-responders” and were randomly assigned to either receive the appetite suppressant phentermine (15.0 mg per day) or a placebo, alongside continued behavioral therapy for an additional 24 weeks.
Phentermine, approved by the U.S. Food and Drug Administration (FDA) in 1959, remains the oldest weight-loss drug available. The results were striking: participants taking phentermine lost an average of 5.9% of their starting weight over the six-month period, more than double the 2.8% loss experienced by those on a placebo. For example, a person weighing 250 pounds would shed approximately 15 pounds with phentermine compared to 7 pounds with placebo.
In contrast, participants who responded well from the start of the behavioral therapy—referred to as “early strong responders”—continued the program without medication and lost an additional 5.1% of their initial weight.
A Promising Approach to Weight Loss
The findings suggest that early intervention with anti-obesity medications could be critical for patients who struggle to see progress with behavioral therapy alone. “Our results strongly support adding anti-obesity medications for patients who don’t achieve meaningful weight loss with behavioral methods alone,” Dr. Tronieri stated. “Introducing the medication early can prevent discouragement and improve adherence, as patients who see early results are more likely to stay committed to treatment.”
The research team hopes this study will guide healthcare professionals in supporting patients who find it difficult to lose weight with diet and exercise alone. However, the study also highlights the need for further testing to assess the effectiveness of newer FDA-approved weight-loss medications, such as semaglutide or tirzepatide, in similar patient populations.
Dr. Thomas A. Wadden, a study co-author, speculated, “If early non-responders were treated with newer medications, like semaglutide or tirzepatide, their weight loss could potentially double or even triple compared to phentermine.” However, he added that further research is needed to confirm this hypothesis.
The study opens the door for a more personalized and timely approach to treating obesity, suggesting that integrating pharmacological support earlier in the treatment process can lead to more sustainable weight loss outcomes.
Related Topics:
Weight-Loss Drugs Like Wegovy Linked to Increased Risk of Hair Loss
Mother of Four Collapses and Vomits Blood After Using Weight Loss Jab
